Safety and Tolerability Clinical Trial
Official title:
An Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin After Single and Multiple Doses Administered Orally in Healthy Volunteers
This study investigates the safety, tolerability, and PK profile of finafloxacin as a novel fluoroquinolone and a potential therapeutic agent for lower respiratory infections such as bacterial pneumonia. A comparison of the PK profile of finafloxacin in plasma and lung ELF using different bronchoscopic ELF sampling techniques (BMS and BAL) is conducted.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000891 -
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
|
Phase 1 | |
Active, not recruiting |
NCT05997641 -
Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06181760 -
A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT05907382 -
Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01952548 -
Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers
|
Phase 1 | |
Recruiting |
NCT06453824 -
SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants
|
Phase 1 | |
Completed |
NCT05431634 -
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT06331884 -
Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)
|
Phase 1 | |
Completed |
NCT03046589 -
DP13 SAD & MAD in Healthy Male Subjects
|
Phase 1 | |
Recruiting |
NCT06079541 -
Phase 1 Clinical Study of JMKX003142 Tablets
|
Phase 1 | |
Completed |
NCT05223660 -
A Phase I Pharmacokinetics Study for KT07 Capsule
|
Phase 1 | |
Completed |
NCT03809052 -
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03853421 -
Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin
|
Phase 1 | |
Terminated |
NCT03307512 -
PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD
|
Phase 2 | |
Completed |
NCT03702231 -
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
|
Phase 2 | |
Completed |
NCT03685708 -
HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
|
Phase 2 | |
Completed |
NCT03817346 -
Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT01226316 -
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
|
Phase 1 | |
Completed |
NCT05451667 -
Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02029482 -
Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects
|
Phase 1 |